F-star Therapeutics is a clinical-stage biopharmaceutical company. Co. is engaged in the discovery and development of therapeutics for the treatment of a range of cancers and inflammatory diseases. Co.'s STING (STimulator of INterferon Genes) product portfolio include STING agonist clinical program in oncology, STING antagonist compounds for inflammatory diseases, and STING agonist antibody drug conjugate program for oncology. Co. is developing its SB 11285, as an immunotherapeutic cyclic dinucleotide for the treatment of selected cancers. Co. is also exploring the use of its STING antagonist compounds for the treatment of certain autoimmune and inflammatory diseases. The FSTX stock yearly return is shown above.
The yearly return on the FSTX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the FSTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|